Short Interest in Zealand Pharma A/S (OTCMKTS:ZLDPF) Expands By 39.7%

Zealand Pharma A/S (OTCMKTS:ZLDPF) was the target of a large increase in short interest in the month of December. As of December 31st, there was short interest totalling 1,166,300 shares, an increase of 39.7% from the December 15th total of 835,100 shares. Based on an average daily trading volume, of 2,100 shares, the days-to-cover ratio is currently 555.4 days.

Analyst Upgrades and Downgrades

Separately, JPMorgan Chase & Co. started coverage on Zealand Pharma A/S in a report on Friday, November 8th. They issued an “overweight” rating for the company.

Zealand Pharma A/S Trading Down 1.9 %

ZLDPF opened at $95.29 on Thursday. The stock has a market cap of $4.91 billion, a PE ratio of -39.21 and a beta of 0.89. The company has a quick ratio of 35.49, a current ratio of 35.49 and a debt-to-equity ratio of 0.03. The business has a 50 day moving average of $104.95 and a 200-day moving average of $119.05. Zealand Pharma A/S has a 52 week low of $64.10 and a 52 week high of $141.74.

About Zealand Pharma A/S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.